Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 1261 to 1270 of 1349 total matches.

Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
of bupivacaine/ meloxicam ER solution was based on the results of 3 randomized, double-blind, active ...
The FDA has approved a fixed-dose combination of the amide local anesthetic bupivacaine and the nonsteroidal anti-inflammatory drug (NSAID) meloxicam as an extended-release (ER) solution (Zynrelef – Heron) for single-dose, intraoperative, soft-tissue or periarticular instillation to provide postsurgical analgesia for up to 72 hours in adults undergoing foot and ankle, small-to-medium open abdominal, or lower extremity total joint arthroplasty surgical procedures.
Med Lett Drugs Ther. 2022 Jan 24;64(1642):13-5 |  Show IntroductionHide Introduction

Comparison Table: Drugs for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
activity can cause additive toxicity ▶ Alcohol-induced dose-dumping with 40% alcohol, but not with lower ...
View the Comparison Table: Drugs for Alzheimer's Disease
Med Lett Drugs Ther. 2022 Aug 22;64(1657):e136-7 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
-drug antibodies with in vitro neutralizing activity have developed; clinical significance unknown ...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2   doi:10.58347/tml.2023.1678c |  Show IntroductionHide Introduction

Intravenous Acetaminophen/Ibuprofen (Combogesic IV)

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024  (Issue 1701)
impairment and is contraindicated in patients with severe hepatic impairment or severe active liver disease ...
The FDA has approved Combogesic IV (Hikma), an IV solution containing acetaminophen and ibuprofen, to treat mild to moderate pain (alone) or moderate to severe pain (in combination with an opioid) in adults when IV analgesia is considered clinically necessary. Single-drug IV solutions containing ibuprofen (Caldolor) and acetaminophen have been available in the US for years.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):68-9   doi:10.58347/tml.2024.1701c |  Show IntroductionHide Introduction

Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
levels of HIF may stimulate cancer growth; use of vadadustat is not recommended in patients with active ...
The FDA has approved the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) vadadustat (Vafseo – Akebia) for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 3 months. Vadadustat is the second HIF-PHI to be approved in the US for this indication; daprodustat (Jesduvroq) was approved earlier, but it was withdrawn from the US market in 2024 for commercial reasons.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):27-9   doi:10.58347/tml.2025.1722b |  Show IntroductionHide Introduction

Cancer Screening

   
Treatment Guidelines from The Medical Letter • Dec 01, 2012  (Issue 124)
following onset of sexual activity. Almost 50% of women ages 20-24 have HPV infection2; however ...
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Treat Guidel Med Lett. 2012 Dec;10(124):87-94 |  Show IntroductionHide Introduction

Vaccines for Travelers

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018  (Issue 1560)
vaccines and, depending on their destination, duration of travel, and planned activities, may also ...
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine...
Med Lett Drugs Ther. 2018 Nov 19;60(1560):185-92 |  Show IntroductionHide Introduction

Drugs for Anxiety Disorders

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
are stopped abruptly. Onset of withdrawal depends on the drug’s half-life and the presence of active ...
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8   doi:10.58347/tml.2023.1682a |  Show IntroductionHide Introduction

Drugs for Psychotic Disorders

   
The Medical Letter on Drugs and Therapeutics • Dec 19, 2016  (Issue 1510)
-generation antipsychotics except for paliperidone, which is the active metabolite of risperidone). At doses ...
Oral antipsychotic drugs used for treatment of schizophrenia, schizoaffective disorder, delusional disorder, and other manifestations of psychosis or mania are listed in Table 1. Parenteral antipsychotic drugs used for treatment of these disorders are listed in Table 2.
Med Lett Drugs Ther. 2016 Dec 19;58(1510):160-4 |  Show IntroductionHide Introduction

Drugs for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
and urine storage (urgency, frequency, nocturia). Activation of beta-3 receptors in the bladder causes ...
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Med Lett Drugs Ther. 2022 May 2;64(1649):65-9 |  Show IntroductionHide Introduction